Focused on developing innovative drugs that materially benefit patients with liver and gastrointestinal diseases

Non-alcoholic steatohepatitis (NASH) is one of the most common liver diseases

Irritable bowel syndrome with diarrhea affects ˜9 million people in the US

Inflammatory bowel disease is increasing in prevalence worldwide

Our Company

We are an experienced team with internal drug discovery and development expertise focused on building a pipeline of best-in-class oral drugs for liver and gastrointestinal diseases.

MET409 is an optimized next generation FXR agonist with a potential role in the treatment of non-alcoholic steatohepatitis (NASH), irritable bowel syndrome with diarrhea and inflammatory bowel diseases. Beyond our FXR program, we are focused on building a pipeline of novel drug candidates.

Focused on developing innovative drugs that materially benefit patients with liver and gastrointestinal diseases

Non-alcoholic steatohepatitis (NASH) is one of the most common liver diseases

Irritable bowel syndrome with diarrhea affects ˜9 million people in the US

Inflammatory bowel disease is increasing in prevalence worldwide

Our Company

Latest News

Metacrine to Present Rapid Efficacy of MET409 in a NASH Mouse Model at The Liver Meeting 2018

Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors

Programs